You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

 

Online download statistics by month:

Online download statistics by month: August 2021 to November 2023

AbstractFullPdf
Aug 202111021113307
Sep 2021354355153
Oct 202131231265
Nov 202133933862
Dec 202132432443
Jan 202226426870
Feb 202225125660
Mar 202214414947
Apr 202214314562
May 202212113351
Jun 202215916039
Jul 202224324453
Aug 202234334784
Sep 202226826755
Oct 202220220247
Nov 202219419762
Dec 202218919038
Jan 202316316532
Feb 202313713738
Mar 202313013141
Apr 202311711740
May 202310110138
Jun 202313713940
Jul 202314914949
Aug 202312412326
Sep 2023909038
Oct 2023989838
Nov 202310110135
Total629963511713